{"id":"https://openalex.org/W2589849042","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11069","title":"A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2-positive early breast cancer.","display_name":"A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2-positive early breast cancer.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2589849042","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11069","mag":"2589849042"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.e11069","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11069","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11069","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037494606","display_name":"I. H. Park","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I. H. Park","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080287282","display_name":"K. S. Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. S. Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032946641","display_name":"Han\u2010Sung Kang","orcid":"https://orcid.org/0000-0002-0609-4293","observed_orcids":["https://orcid.org/0000-0002-0609-4293"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. S. Kang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Y. Kwon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y. Kwon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005144573","display_name":"S. W. Kim","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. W. Kim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113427958","display_name":"Seungjun Lee","orcid":"https://orcid.org/0009-0000-6355-3225","observed_orcids":["https://orcid.org/0009-0000-6355-3225"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012046553","display_name":"Su Yon Jung","orcid":"https://orcid.org/0000-0002-0513-1830","observed_orcids":["https://orcid.org/0000-0002-0513-1830"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Y. Jung","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111975003","display_name":"Kichul Shin","orcid":"https://orcid.org/0000-0002-6749-7598","observed_orcids":["https://orcid.org/0000-0002-6749-7598"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. H. Shin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111313659","display_name":"K. Ko","orcid":"https://orcid.org/0000-0002-5278-4092","observed_orcids":["https://orcid.org/0000-0002-5278-4092"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Ko","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108388975","display_name":"Byung\u2010Ho Nam","orcid":"https://orcid.org/0009-0001-5652-7317","observed_orcids":["https://orcid.org/0009-0001-5652-7317"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Nam","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5109197018","display_name":"J. Ro","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Ro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"e11069","last_page":"e11069"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9258000254631042,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9258000254631042,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.060499999672174454,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.005100000184029341,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.8560000061988831},{"id":"https://openalex.org/keywords/early-breast-cancer","display_name":"early breast cancer","score":0.9210000038146973},{"id":"https://openalex.org/keywords/lapatinib","display_name":"lapatinib","score":0.8450000286102295},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9869999885559082},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":1.0},{"id":"https://openalex.org/keywords/neoadjuvant-chemotherapy","display_name":"neoadjuvant chemotherapy","score":0.9860000014305115},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7689999938011169},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8600000143051147},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.7770000100135803},{"id":"https://openalex.org/keywords/breast-conserving-surgery","display_name":"breast-conserving surgery","score":0.8899999856948853},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.8939999938011169},{"id":"https://openalex.org/keywords/adjuvant-endocrine-therapy","display_name":"adjuvant endocrine therapy","score":0.7400000095367432},{"id":"https://openalex.org/keywords/left-ventricular-ejection-fraction","display_name":"left ventricular ejection fraction","score":0.7039999961853027}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9379372596740723},{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.9371227025985718},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.7802695035934448},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6432927250862122},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6051037311553955},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.5976645350456238},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5201618671417236},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.46886876225471497},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4583297669887543},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.42773401737213135},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3997885286808014},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.37642771005630493}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.e11069","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11069","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.e11069","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2603067917","https://openalex.org/W2046376183","https://openalex.org/W2055235037","https://openalex.org/W2325687878","https://openalex.org/W2068648528","https://openalex.org/W7097815625","https://openalex.org/W1978434864","https://openalex.org/W2111578514","https://openalex.org/W1977737254","https://openalex.org/W2302523915"],"abstract_inverted_index":{"e11069":[0],"Background:":[1],"Previously,":[2],"we":[3],"reported":[4],"that":[5],"the":[6,18,37,151,159],"addition":[7],"of":[8,20,67,204,211,268],"trastuzumab":[9],"to":[10,35,69,110],"paclitaxel/gemcitabine":[11],"as":[12,52,123],"neoadjuvant":[13],"chemotherapy(NCT)":[14],"had":[15],"significantly":[16],"increased":[17],"rate":[19],"pCR":[21],"in":[22,54,201,288],"HER2":[23,55],"positive":[24,56],"early":[25],"breast":[26,234],"cancer":[27],"(EBC).":[28],"We":[29],"conducted":[30],"a":[31,42,102,289],"phase":[32,61,290],"I":[33,62],"trial":[34],"determine":[36],"feasible":[38],"dose":[39,63,244],"for":[40,120,158,314,318,323],"lapatinib,":[41,315],"dual":[43],"HER2/EGFR":[44],"tyrosine":[45],"kinase":[46],"inhibitor,":[47],"with":[48,129,217],"paclitaxel":[49,79,166,271],"and":[50,85,87,96,115,135,168,173,224,246,258,272,276,304,320],"gemcitabine":[51,88,169,273],"NCT":[53],"EBC.":[57],"Methods:":[58],"In":[59],"this":[60],"escalation":[64],"study,":[65],"cohorts":[66],"3":[68,187,190,218],"6":[70],"patients":[71,128,139,191,213,219,231,260],"received":[72],"lapatinib":[73,108,162,208,243,263,269],"(1,000mg":[74],"or":[75,90],"1,250mg":[76],"PO,":[77],"daily),":[78],"(80mg/m2,":[80],"IV":[81,92],"on":[82,93,262],"day":[83,94],"1":[84,95,112,172,182],"8),":[86],"(1,000":[89],"1,200mg/m2,":[91],"8)":[97],"every":[98,175],"21":[99,176],"days":[100,171],"using":[101],"standard":[103],"3+3":[104],"design.":[105],"Patients":[106],"undergo":[107],"maintenance":[109],"complete":[111],"year":[113],"treatment":[114],"receive":[116],"adjuvant":[117],"hormone":[118],"therapy":[119],"5":[121,225],"years":[122],"indicated.":[124],"Results:":[125],"Among":[126],"13":[127],"EBC":[130],"enrolled":[131],"between":[132,242],"August":[133],"2009":[134],"June":[136],"2010,":[137],"12":[138,180,212],"(stage":[140],"III;":[141],"11:":[142],"stage":[143],"II;":[144],"1)":[145],"completed":[146],"treatment.":[147,209],"One":[148],"patient":[149,183],"withdrew":[150],"consent.":[152],"The":[153,266],"maximum":[154],"tolerated":[155],"doses":[156],"(MTD)":[157],"combination":[160,267],"were":[161,309],"1000mg":[163],"once":[164],"daily,":[165],"80mg/m2":[167],"1000mg/m2":[170],"8":[174],"days.":[177],"Of":[178],"these":[179],"patients,":[181],"developed":[184],"dose-limiting":[185,192],"grade":[186,193],"transaminase":[188],"elevation;":[189],"4":[194],"neutropenia.":[195],"There":[196,237],"was":[197,238,252,274,278],"no":[198,239,279],"notable":[199],"decline":[200],"ejection":[202],"fraction":[203],"left":[205],"ventricle":[206],"during":[207],"Eleven":[210],"showed":[214],"clinical":[215,292],"PR":[216],"(25%)":[220],"achieved":[221,227],"total":[222],"pCR,":[223],"(42%)":[226],"tumor":[228,247],"pCR.":[229],"Six":[230],"(50%)":[232],"underwent":[233],"conserving":[235],"surgery.":[236],"apparent":[240],"relationship":[241],"intensity":[245],"response.":[248],"Median":[249],"follow-up":[250],"duration":[251],"16.2":[253],"months":[254],"(range,":[255],"6.5-20.7":[256],"months)":[257],"three":[259],"are":[261],"maintenance.":[264],"Conclusions:":[265],"plus":[270],"tolerable":[275],"there":[277],"overlapping":[280],"toxicity.":[281],"Antitumor":[282],"activity":[283],"should":[284],"be":[285],"further":[286],"assessed":[287],"II":[291],"trial.":[293],"Clinicaltrial.gov":[294],"#":[295],"NCT01133912.":[296],"Funded":[297],"by":[298,305,311],"National":[299],"Cancer":[300],"Center":[301],"Grant":[302],"0910320-3":[303],"GSK.":[306],"Study":[307],"drugs":[308],"supplied":[310],"GlasoSmithKline":[312],"Korea":[313],"ShinPoong":[316],"Pharm.Co.LTD":[317],"gemcitabine,":[319],"CJ":[321],"Cheiljedang":[322],"paclitaxel.":[324]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2017-03-03T00:00:00"}